HealthFlex
×
  • About Us
    • Company Management
    • Meet Our Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
    • Careers
  • Technologies
    • Oncoprex® Delivery System
    • Reqorsa® Gene Therapy
    • GPX-002
  • Programs
    • Oncology
    • Diabetes
  • Clinical Trials
    • Pipeline
    • ONC-001
    • ONC-002
    • Acclaim-1
    • Acclaim-3
    • DIA-001 and DIA-002
    • Expanded Access Policy
  • Investors
    • Company Profile
    • Stock Information
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder FAQ
    • Downloads
    • Events
  • News
    • Press Releases
    • Blog Posts
    • Media Coverage
    • Videos
  • Contact
Olivia Stancil

Olivia Stancil

In-House Clinical Research Associate

Olivia Stancil serves as Genprex’s In-House Clinical Research Associate where she supports the clinical operations team with the preparation, handling, distribution, filing, and archiving of clinical trial documentation. Mrs. Stancil acts as both a Functional Trial Master File (TMF) Specialist and a Clinical Trial Management System (CTMS) Specialist.

Mrs. Stancil brings a wide breadth of experience ranging from multiple industries across multiple roles to the Genprex team. Prior to joining Genprex, she started her career in pharmaceutical sales with Johnson & Johnson and went on to carry a management leadership role for ten years in a non-profit that provided cancer support services and resources to oncology patients and their families. Most recently, she spent two years at PSI CRO providing support for oncology and diabetes clinical trials.  Mrs. Stancil graduated from Michigan State University with a Bachelor of Science from the College of Agriculture and Natural Resources.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

(877) 774-GNPX (4679)

3300 Bee Cave Road, Suite 650-227 Austin, TX 78746

Quick Links

  • About Us
  • Clinical Trials
  • Investors
  • Downloads
  • Press Releases
  • X
  • Facebook
  • LinkedIn

Latest News

  • Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer Apr 30
  • Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting Apr 28
  • Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting Apr 22
  • Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy Apr 21
Designed and Secured by Barsec
Copyright ©2026 all rights reserved.
Home - Privacy Policy - Terms of Use